Showing 1 – 20 of 55
Relevance | Newest | Oldest |
  • Comparison of Vascular Closure Devices vs Manual Compression After Femoral Artery Puncture: The ISAR-CLOSURE Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2014; 312(19):1981-1987. doi: 10.1001/jama.2014.15305

    This randomized clinical trial of 4524 patients undergoing transfemoral coronary angiography reports that vascular closure devices were noninferior to manual compression in terms of vascular access-site complications and reduced time to hemostasis.

  • JAMA November 14, 2001

    Figure 4: Representative Examples of the Major Differences Between the Predicted Protein Sets of the Human Compared With the Fly and the Worm

    The numbers of proteins containing the specified Pfam domain or protein family for each of the animal genomes were derived by computational analysis. Representative protein domains or protein families that show a 2-fold or greater expansion in the human were categorized into cellular processes (eg, developmental regulators; neural structure and function; or hemostasis, complement system, and immune response) for representation. A detailed biological description of each of these protein domains may be obtained from the Pfam or SMART databases. TGF-β indicates transforming growth factor-β; TSP, thrombospondin; CCP, complement control protein; and TIR, toll interleukin receptor.Notable examples from this list of proteins that are unique to the human (when compared with the fly and worm) include connexins (constitutive subunits of intercellular channels, providing the structural basis for electrical coupling); neuropilin, a key mediator in axonal guidance along with the semaphorins and plexin molecules; fibronectin type 1 (FN1) domain, a fibrin-binding domain found in certain proteins of the coagulation cascade; fibronectin type 2 (FN2) domain, a collagen-binding domain found in a diverse set of hemostatic regulators; membrane-attack complex/perforin (MACPF), a domain found in certain complement proteins; C1q, a domain found in complement 1q and in many collagens; cytokines and tumor necrosis factor (TNF), 2 of the central families of secreted proteins that mediate a wide spectrum of immune-related functions.*Voltage-gated (VG) ion channels include VG-sodium, -calcium, and -potassium channels.
  • Hyperinsulinemia, Hyperglycemia, and Impaired Hemostasis: The Framingham Offspring Study

    Abstract Full Text
    free access
    JAMA. 2000; 283(2):221-228. doi: 10.1001/jama.283.2.221
  • Complications Related to Vascular Hemostasis Devices

    Abstract Full Text
    JAMA. 1999; 282(21):1995-1995. doi: 10.1001/jama.282.21.1995
  • Emergency Management of Unexpected Defects of Hemostatic Function in Surgical Patients

    Abstract Full Text
    JAMA. 1967; 201(2):123-126. doi: 10.1001/jama.1967.03130020069017
  • Studies on Hemostatic Function in Paroxysmal Nocturnal Hemoglobinuria

    Abstract Full Text
    JAMA. 1963; 184(8):161-161. doi: 10.1001/jama.1963.03700210115067

    Abstract Full Text
    JAMA. 1967; 201(2):129-130. doi: 10.1001/jama.1967.03130020075021
  • Bleeding and Clotting Time Determinations

    Abstract Full Text
    JAMA. 1961; 176(13):1126-1126. doi: 10.1001/jama.1961.03040260060021
  • Effect of Hypobaric Hypoxia, Simulating Conditions During Long-Haul Air Travel, on Coagulation, Fibrinolysis, Platelet Function, and Endothelial Activation

    Abstract Full Text
    free access
    JAMA. 2006; 295(19):2251-2261. doi: 10.1001/jama.295.19.2251

    Abstract Full Text
    JAMA. 1957; 164(13):1468-1469. doi: 10.1001/jama.1957.62980130004010b
  • JAMA July 25, 2017

    Figure 1: Screened, Excluded, and Included Patients in the Study of Targeted Temperature Management

    OHCA indicates out-of-hospital cardiac arrest; ICU, intensive care unit; ROSC, return of spontaneous circulation.aReasons for not meeting inclusion (eligibility) criteria were as follows: not cardiac OHCA (n=75), age (n=53), Glasgow Coma Scale score >8 (n=49), and no stable ROSC (n=14).bExclusion criteria met were as follows: estimated time from collapse to ROSC >60 min (n=40), cardiac arrest with presumed noncardiac cause (eg, trauma, aorta dissection, intracerebral disease, massive bleeding, hanging, or hypoxemia) (n=63), in-hospital cardiac arrest (n=6), terminal disease or do-not-resuscitate order (n=15), severe coagulopathy (anticoagulant therapy, including thrombolysis, was not an exclusion criteria) (n=8), unwitnessed OHCA with asystole as first rhythm (n=21), time from cardiac arrest to initiation of cooling >240 min (n=19), neurologic disease with cognitive impairment (n=8), persistent cardiogenic shock, systolic blood pressure <80 mm Hg despite vasoactive treatment, or aortic balloon pump intervention (n=46), suspected or confirmed acute intracerebral bleeding (n=9), suspected or confirmed acute stroke (n=6), and acute coronary artery bypass surgery (n=1).cOther reasons for exclusion were as follows: patient died before enrollment (n=10), other interventional study precluding co-enrollment (n=5), patients transferred to other ICU because of bed availability (n=5), and patient not native to country of treatment, rendering follow-up difficult or impossible (n=3).dThe patient lost to follow-up was known to be alive and was included in the survival analyses, but could not be included in the primary analyses due to lack of primary outcome data.
  • Mixing Study for Evaluation of Abnormal Coagulation Testing

    Abstract Full Text
    JAMA. 2016; 316(20):2146-2147. doi: 10.1001/jama.2016.15749

    An 84-year-old woman with a history of chronic kidney disease, prior stroke, and hypertension but no personal or family history of bleeding disorders was admitted with a 2-week history of spontaneous subcutaneous ecchymoses and hematomas. She had normal vital signs, laboratory results showing isolated severe anemia but unremarkable for other causes of anemia, and a large soft-tissue hematoma in the left chest wall without evidence of internal hemorrhage. How do you interpret these test results?

  • Cutaneous Necrosis of the Ears

    Abstract Full Text
    JAMA. 2016; 316(4):450-451. doi: 10.1001/jama.2016.7847

    A 22-year-old woman presented with a 2-month history of fevers and pleuritic chest pain and a 2-day history of cutaneous necroses on her ears, without trauma. Evaluation revealed abnormal coagulation values and a deep vein thrombosis in one leg. What would you do next?

  • JAMA February 23, 2016

    Figure 4: Serum Lactate Level Analysis

    Adjusted odds ratio for actual serum lactate levels for the entire septic shock cohort (N = 18 840). The covariates used in the regression model include region (United States and Europe), location where sepsis was suspected (emergency department, ward, or critical care unit), antibiotic administration, steroid use, organ failures (pulmonary, renal, hepatic, and acutely altered mental state), infection source (pneumonia, urinary tract infection, abdominal, meningitis, and other), hyperthermia (>38.3°C), hypothermia (<36°C), chills with rigor, tachypnea (>20/min), leukopenia (<4000 cells/µL), hyperglycemia (plasma glucose >120 mg/dL [6.7 mmol/L]), platelet count <100 ×103/μL, and coagulopathy (eMethods 3 in the Supplement). The adjusted odds ratio (OR) for the 6 groups presented in eTable 7 in the Supplement and the adjusted OR for the individual variables (lactate, vasopressor therapy, and fluids) are reported in eTable 8 in the Supplement. To convert serum lactate values to mg/dL, divide by 0.111.
  • New Option for Bleeding Disorder

    Abstract Full Text
    JAMA. 2016; 315(3):243-243. doi: 10.1001/jama.2015.18731
  • Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma: The PROPPR Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2015; 313(5):471-482. doi: 10.1001/jama.2015.12

    This randomized trial reports that among patients with severe trauma and major bleeding, early administration of plasma, platelets, and red blood cells in a 1:1:1 ratio compared with a 1:1:2 ratio did not result in significant differences in mortality at 24 hours or at 30 days.

  • Storage Duration and Other Measures of Quality of Red Blood Cells for Transfusion

    Abstract Full Text
    JAMA. 2015; 314(23):2509-2510. doi: 10.1001/jama.2015.14714
  • Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa

    Abstract Full Text
    free access
    JAMA. 2006; 295(3):293-298. doi: 10.1001/jama.295.3.293
  • Stroke Prevention in Atrial Fibrillation: A Systematic Review

    Abstract Full Text
    is active quiz
    JAMA. 2015; 313(19):1950-1962. doi: 10.1001/jama.2015.4369

    This narrative review summarizes stroke risk prediction tools and strategies to prevent stroke in patients with atrial fibrillation.